研究者詳細 - 赤穂　宗一郎

論文 - 赤穂　宗一郎

分割表示 37 件中 21 - 37 件目／全件表示 >>

Gastric Adenocarcinoma and Proximal Polyposis of the Stomach Occurring With Ball Valve Syndrome. 国際誌

Soichiro Ako, Seiji Kawano, Hiroyuki Okada

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20 ( 2 ) e12-e13 2020年7月

Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma. 国際誌

Soichiro Ako, Kazuhiro Nouso, Hideaki Kinugasa, Hiroshi Matsushita, Hiroyuki Terasawa, Takuya Adachi, Nozomu Wada, Yasuto Takeuchi, Mari Mandai, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Shinichi Fujioka, Tetsushige Mimura, Hiroyuki Okada

Oncology 98 ( 5 ) 311 - 317 2020年

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Mutations in the human telomerase reverse transcriptase (hTERT) gene promoter have been reported in hepatocellular carcinoma (HCC); however, analyses of these mutations in liquid biopsies have been technically difficult because of the high GC content of the regions of interest within this promoter. We evaluated the feasibility and prognostic value of hTERT promoter mutations identified in circulating cell-free DNA (cfDNA) from the serum of patients with HCC. OBJECTIVE: A cohort of HCC patients (n = 36) who were curatively treated by surgical resection between June 2003 and September 2014 were enrolled in this study. METHODS: The presence of hTERT promoter mutations in cfDNA from the patients' serum was analyzed via modified droplet digital polymerase chain reaction, and associations were sought between specific promoter mutations and patients' disease-free survival (DFS). RESULTS: The G>A hTERT mutation at -124 bp was detected in the serum of 25 patients (69%). Although no marked differences were observed between the characteristics of the serum mutation-positive and serum mutation-negative patient groups, the DFS of patients with the mutation was significantly shorter than that of the serum mutation-negative patients (p = 0.02). Among 18 clinicopathologic and background liver factors examined, the presence of the -124 bp G>A mutation was an independent and significant predictor of patients' DFS (hazard ratio = 3.01, 95% confidence interval 1.11-10.5, p = 0.03) in multivariate analyses. CONCLUSIONS: The -124 bp G>A hTERT promoter mutation was observed in the serum of 69% of HCC patients who underwent surgical resection and was an independent predictor of disease progression in HCC.

DOI： 10.1159/000506135

PubMed

researchmap

Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. 国際誌

Hiroyuki Terasawa, Hideaki Kinugasa, Soichiro Ako, Mami Hirai, Hiroshi Matsushita, Daisuke Uchida, Takeshi Tomoda, Kazuyuki Matsumoto, Shigeru Horiguchi, Hironari Kato, Kazuhiro Nouso, Hiroyuki Okada

Cancer biology & therapy 20 ( 10 ) 1348 - 1353 2019年

記述言語：英語掲載種別：研究論文（学術雑誌）

In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48%) in urine and 27 cases (48%) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70% (14/20) and 36% (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively (P = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50% (10/20) and 47% (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.

DOI： 10.1080/15384047.2019.1638685

PubMed

researchmap

[Metachronous intraductal papillary mucinous carcinoma five years after cholecystectomy for gallbladder cancer in a patient with pancreaticobiliary maljunction]. 査読

Ikeda A, Matsumoto K, Kato H, Tanaka N, Ako S, Muro S, Uchida D, Tomoda T, Horiguchi S, Okada H

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 116 ( 3 ) 241 - 248 2019年

Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation.

Soichiro Ako, Shinichiro Nakamura, Kazuhiro Nouso, Chihiro Dohi, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

Acta medica Okayama 72 ( 1 ) 47 - 52 2018年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p< 0.01) and a long interval between the therapies (p= 0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size.

DOI： 10.18926/AMO/55662

PubMed

researchmap

Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer. 国際誌

Hideaki Kinugasa, Kazuhiro Nouso, Soichiro Ako, Chihiro Dohi, Hiroshi Matsushita, Kazuyuki Matsumoto, Hironari Kato, Hiroyuki Okada

Cancer biology & therapy 19 ( 10 ) 934 - 938 2018年

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Tissue sampling of gallbladder cancer (GBCa) is challenging because of the anatomy of the gallbladder. The aim of this study is to investigate the possibility of diagnosing GBCa patients by performing a liquid biopsy of bile in addition to current diagnostic methods. METHODS: Thirty patients with GBCa were enrolled in this study. Cytological examination was performed in all patients. Using next generation sequencing (NGS), DNA isolated from the bile and tumor tissue was analyzed for mutations in 49 oncogenes. We also compared these mutations with cytology results. RESULTS: 57.1% of DNA samples from tumor tissue were positive for a mutation. In these patients, 87.5% of the bile circulating tumor DNA (ctDNA) samples had the same mutation. The concordance rate between bile ctDNA and tissue DNA samples was 85.7%, and the mutation frequencies detected in ctDNA were approximately half of what was detected in tumor tissue DNA. On the other hand, the sensitivity of the cytological and bile ctDNA analyses was 45.8% and 58.3%, respectively. The concordance rate between cytology and bile ctDNA analyses was 87.5%. CONCLUSIONS: Mutated tumor DNA could be detected in bile by NGS. Liquid biopsy of bile might help us to diagnose GBCa because of higher sensitivity and positive predict value compared to cytology with ERCP.

DOI： 10.1080/15384047.2018.1456604

PubMed

researchmap

A case of liver capillary hemangioma with cystic lesions 査読

Soichiro Ako, Ryuichi Kita, Eriko Iguchi, Yorimitsu Koshikawa, Haruhiko Takeda, Tadashi Inuzuka, Jun Nakajima, Fumihiro Matsuda, Tetsuro Ishikawa, Azusa Sakamoto, Shinichiro Henmi, Sumio Saito, Hiroki Nishikawa, Toru Kimura, Yukio Osaki, Akiko Wakasa, Osamu Nakashima

Acta Hepatologica Japonica 59 ( 3 ) 187 - 193 2018年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Japan Society of Hepatology

Hepatic capillary hemangioma is a rare hepatic benign tumor which composed of the aggregation of capillary vessels. Because of the difficulty of diagnosis, there are some reports diagnosed by surgical resection. We reported the case of liver capillary hemangioma with cystic lesions which was diagnosed by single level dynamic CT and fine-needle targeted biopsy. A patient was female in the sixties. Screening examination by magnetic resonance imaging (MRI) pointed out the tumor in the 6th segment of liver. Contrast enhanced CT revealed that tumor was strongly enhanced in the arterial phase. Washout pattern was observed at equilibrium phase. Single level dynamic CT during hepatic arteriography showed spotted enhanced followed to enhanced homogeneously, which might reveal the characteristic of capillary vessels in the tumor. The tumor tissue obtained by fine-needle biopsy showed the aggregation of capillary vessels positively immuno-stained with CD34 and factor VIII, that lead to diagnose hepatic capillary hemangioma.

DOI： 10.2957/kanzo.59.187

Scopus

researchmap

Comparing reduced-dose sodium phosphate tablets to 2 L of polyethylene glycol: A randomized study. 国際誌

Soichiro Ako, Koji Takemoto, Eriko Yasutomi, Chihiro Sakaguchi, Mayu Murakami, Tomoko Sunami, Shohei Oka, Hamada Kenta, Noriko Okazaki, Yuki Baba, Yasushi Yamasaki, Toshiyuki Asato, Daisuke Kawai, Ryuta Takenaka, Hirohumi Tsugeno, Sakiko Hiraoka, Jun Kato, Shigeatsu Fujiki

World journal of gastroenterology 23 ( 24 ) 4454 - 4461 2017年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

AIM: To compare the tolerability and quality of bowel cleansing between 2 L polyethylene glycol (PEG) and reduced-dose sodium phosphate (NaP) tablets as a preparation for colonoscopy. METHODS: Two hundred patients were randomly assigned to the PEG or NaP groups at the same ratio. The NaP group patients took 30 tablets with 2 L of clear liquid, while the PEG group patients took 2L of PEG. Tolerability was assessed by a questionnaire about taste, volume, and the overall impression. The bowel cleansing quality was evaluated by colonoscopists. RESULTS: Although NaP showed better tolerability in terms of taste, volume and overall impression (P < 0.01, P < 0.01 and P = 0.02, respectively), the overall cleansing quality was better in the PEG group (P < 0.01). A subgroup analysis, stratified by sex and age, indicated that NaP was associated with better tolerability and equivalent bowel cleansing quality in females of < 50 years of age. CONCLUSION: Despite the better tolerability, the use of 30 NaP tablets with 2 L of clear liquid should be limited due to its lower cleansing quality; however, in certain cases the regimen may deserve consideration, particularly in cases involving young women.

DOI： 10.3748/wjg.v23.i24.4454

PubMed

researchmap

Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma. 国際誌

Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Ayano Oonishi, Akiko Wakuta, Atsushi Oyama, Soichiro Ako, Chihiro Dohi, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

Journal of gastroenterology and hepatology 32 ( 3 ) 695 - 700 2017年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND AND AIM: Transcatheter arterial chemoembolization (TACE) is a standard therapy for the treatment of intermediate-stage hepatocellular carcinoma (HCC). In this study, we tried to elucidate the possibility of using radiofrequency ablation (RFA) as an alternative treatment of intermediate-stage HCC. METHODS: Among 246 patients who were initially diagnosed with intermediate-stage HCC, 76 who were treated with TACE (TACE group) and 91 who were treated with RFA (RFA group) were enrolled in this study. The risk for survival was analyzed with the Cox Proportional Hazard Model, and the survival rates were compared using propensity score matching. RESULTS: About half (50.6%) of the intermediate-stage HCC patients in the RFA group were diagnosed with Barcelona Clinic Liver Cancer substage-B1 (BCLC-B1) compared with only 19.7% of the patients in the TACE group. Survival of the RFA group was longer than that of TACE group in patients with BCLC-B1 and BCLC-B2. In contrast, no difference between groups was observed in patients with BCLC-B3/4. Multivariate analysis revealed that large tumor size (>30 mm, hazard ratio = 1.685, P = 0.043), high des-γ-carboxyprothrombin (>100 mAU/mL, hazard ratio = 1.920, P = 0.012), and TACE group (hazard ratio = 1.896, P = 0.016) were significant risk factors for survival. Overall 3-year survival of the patients in the RFA group (69.5%) was significantly longer than that of patients in the TACE group (51.5%) after propensity score matching (P = 0.032). No significant adverse events were observed in either group. CONCLUSIONS: RFA was useful for the treatment of less advanced intermediate-stage HCC and could be an alternative to TACE in selected cases.

DOI： 10.1111/jgh.13586

PubMed

researchmap

Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue 査読

Soichiro Ako, Kazuhiro Nouso, Hideaki Kinugasa, Chihiro Dohi, Hiroshi Matushita, Sho Mizukawa, Shinichiro Muro, Yutaka Akimoto, Daisuke Uchida, Takeshi Tomoda, Kazuyuki Matsumoto, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Hiroyuki Okada

PANCREATOLOGY 17 ( 2 ) 285 - 290 2017年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE BV

Background/Objectives: The detection of cancer-specific DNA in peripheral blood, known as a liquid biopsy, has been reported recently. Most such studies have used plasma as a sample; however, whether or not serum can be used as effectively is unclear. We attempted to clarify suitable samples for detecting KRAS mutations in circulating DNA in the blood of pancreatic cancer patients using droplet digital polymerase chain reaction (PCR).
Methods: DNA was extracted from the tissue, plasma, and serum of 40 pancreatic cancer patients. The presence of KRAS mutations G12D, G12V, and G12R was analyzed by droplet digital PCR.
Results: The amount of DNA isolated from the serum was much higher than that from plasma (1.0-to 42.0-fold). At least 1 KRAS mutation was observed in 93% of cancer tissues, whereas we detected the mutations in only 48% of the serum and plasma DNA samples. The G12D mutation was the most prevalent of the three mutations, followed by the G12V mutation. The presence of the G12D KRAS mutation in the plasma, serum, or tissue did not correlate to the overall survival; however, the prognosis of the patients with a KRAS mutation at G12V in the plasma or serum was significantly poorer than that of the patients without the mutation (P < 0.01).
Conclusions: Serum and plasma were found to be good materials for detecting cancer-specific DNA in the peripheral blood and the presence of KRAS mutations in blood-derived DNA may be used as a prognostic biomarker for patients with pancreatic cancer. (C) 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

DOI： 10.1016/j.pan.2016.12.011

Web of Science

PubMed

researchmap

A case of gastric volvulus treated by balloon endoscopy

Soichiro Ako, Ryuta Takenaka, Yasufumi Yamasaki, Daisuke Kawai, Koji Takemoto, Akihiko Taira, Hirofumi Tsugeno, Shigeatsu Fujiki

Gastroenterological Endoscopy 57 ( 6 ) 1361 - 1366 2015年6月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Japan Gastroenterological Endoscopy Society

A 63-year-old man was admitted to our hospital for vomitus niger. Chest X-ray showed elevation of the left diaphragm, and computerized tomography revealed that the stomach was extended and rotated on the short axis. Therefore, the diagnosis was gastric volvulus. Because of the extension of the stomach, the upper gastrointestinal endoscopy, which we routinely use, was not able to reach the duodenum. By using balloon endoscopy we were able to reach the third portion of the duodenum, and to fix the volvulus with the balloon. We had success with the noninvasive treatment, and were able to avoid surgical treatment. Balloon endoscopy should be considered as one of the options to treat gastric volvulus.

Scopus

researchmap

The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. 国際誌

Hiroki Nishikawa, Yukio Osaki, Eriko Iguchi, Yorimitsu Koshikawa, Soichiro Ako, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Fumihiro Matsuda, Azusa Sakamoto, Shinichiro Henmi, Keiichi Hatamaru, Tetsuro Ishikawa, Sumio Saito, Akihiro Nasu, Ryuichi Kita, Toru Kimura

Journal of clinical gastroenterology 47 ( 4 ) 359 - 66 2013年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

GOALS: To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of ≤3.5 g/dL. BACKGROUND: Whether BCAA treatment after curative RFA for patients with HCV-related HCC improves OS and RFS remains unclear. STUDY: We compared the OS rate and the RFS rate between the BCAA group (n=115) and the control group (n=141). We also examined factors contributing to OS and RFS. RESULTS: The 1 and 3 years OS rates after RFA were 94.0% and 70.0%, respectively, in the BCAA group, and 94.0% and 49.8%, respectively, in the control group (P=0.001). The corresponding RFS rates 1 and 3 years after RFA were 61.8% and 28.0%, respectively, in the BCAA group, and 52.0% and 12.0%, respectively, in the control group (P=0.013). In the multivariate analysis, in terms of OS, BCAA treatment, and serum albumin level of ≥3.4 g/dL, and in terms of RFS, age 70 years or older, BCAA treatment, and a serum albumin level of ≥3.4 g/dL were significant independent factors, respectively. CONCLUSIONS: BCAA treatment may improve OS and RFS after RFA in patients with HCV-related HCC≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of 3.5 g/dL.

DOI： 10.1097/MCG.0b013e31826be9ad

PubMed

researchmap

[A case of diffuse cystic malformation in which submucosal tumor-like advanced gastric cancer was identified during 10-year follow-up].

Soichiro Ako, Takehiko Tsumura, Yoshihiro Okabe, Akira Sekikawa, Takashi Kanesaka, Tomoko Wakasa, Masayuki Shintaku, Takanori Maruo, Toru Kimura, Yukio Osaki

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 109 ( 11 ) 1910 - 9 2012年11月

記述言語：日本語掲載種別：研究論文（学術雑誌）

A 66-year-old man with giant gastric folds had been followed up since February 2000. In March 2010, a submucosal tumor of 35mm was identified with endoscopy and a low echoic mass was identified with endoscopic ultrasonography. After histologic diagnosis by endosonography-guided fine needle aspiration biopsy, he underwent a total gastrectomy. Histologic examination of the resected specimen revealed a tumor 20mm in diameter consisting of well-to-moderately differentiated tubular adenocarcinoma in the thickened wall of the gastric greater curvature, which contained small cystic lesions in the lamina propria. Immunohistochemical staining showed thick gastric wall consisting of not only multiple cysts but also smooth muscle, elastic and collagen fibers. The histologic diagnosis was advanced gastric cancer accompanied by diffuse cystic malformation (DCM). Although it is a rare condition, DCM should be considered in the differential diagnosis of giant gastric folds and as a pre-cancerous lesion.

PubMed

researchmap

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. 国際誌

Hiroki Nishikawa, Eriko Iguchi, Yorimitsu Koshikawa, Soichiro Ako, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Fumihiro Matsuda, Azusa Sakamoto, Sinichiro Henmi, Keiichi Hatamaru, Tetsuro Ishikawa, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio Osaki

BMC research notes 5 135 - 135 2012年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The clearance of hepatitis C virus infection by interferon therapy significantly reduces the incidence of hepatocellular carcinoma and death in elderly chronic hepatitis patients. However, there are few reports concerning the efficacy and safety of pegylated interferon-alpha2b plus ribavirin combination therapy in elderly patients. The aims of the present study were to examine the effect and safety of pegylated interferon-alpha2b plus ribavirin combination therapy in 427 patients with chronic hepatitis C infection. We compared the rates of sustained virological response--defined as the absence of detectable hepatitis C virus in serum 24 weeks after the treatment ended--and the treatment discontinuation rate between 319 younger patients aged < 65 years and 108 elderly patients aged ≥ 65 years. We also examined the factors contributing to a sustained virological response. RESULTS: There was no significant difference in the sustained virological response rate between younger patients and elderly patients according to their hepatitis C virus genotype (41.5% (100/241) and 40.7% (35/86) for genotype 1; P = 0.899, 89.7% (70/78) and 86.4% (19/22) for genotype 2; P = 0.703, respectively). There was also no significant difference in the treatment discontinuation rate between the two age groups (10.3% (33/319) and 13.9% (15/108), respectively; P = 0.378). There were no serious adverse events requiring hospitalization. The factors contributing significantly to a sustained virological response in elderly patients were gender, hepatitis C virus genotype, platelet count, and the presence of a rapid or early virological response (undetectable hepatitis C virus in serum at weeks 4 or 12 of treatment, respectively). However, upon multivariate analysis, the presence of an early virological response was the only significant factor (odds ratio: 0.115, 95% confidence interval: 0.040- 0.330, P < 0.001). CONCLUSIONS: The efficacy and safety of pegylated interferon-alpha2b plus ribavirin combination therapy in elderly patients are not always inferior to those in younger patients. Obtaining an early virological response may be essential to achieve a sustained virological response in elderly patients with chronic hepatitis C infection.

DOI： 10.1186/1756-0500-5-135

PubMed

researchmap

【細胆管細胞癌】細胆管癌成分を有し濃染する胆管細胞癌の1例

喜多竜一, 原田憲一, 若狭明子, 井口恵里子, 赤穂宗一郎, 竹田治彦, 犬塚義, 中島潤, 石川哲郎, 坂本梓, 木村達, 大崎往夫, 中沼安二

Liver Cancer 17 ( 2 ) 82 - 91 2011年11月

記述言語：日本語出版者・発行元：(株)アークメディア

症例は75歳女性で、C型肝硬変で近医フォロー中、腹部USで肝S8に3cm大の腫瘤、CT等の血流画像で多血性を認め、肝細胞癌(HCC)疑いで紹介入院した。検査ではトランスアミナーゼの軽度高値を認めるが、肝予備能は保たれていた。HCV抗体陽性、HBVは既感染パターン、腫瘍マーカーはCA19-9のみ軽度高値であった。腹部USで径3.5cmの低エコー結節を認め、CTでは淡い低信号、dynamic CTでは早期相で高吸収、後期相で低吸収を呈し、MRIではT1強調で低信号、T2強調で高信号、拡散強調で高信号、EOB肝細胞相で辺縁不整の低信号を呈した。HCC、混合型肝癌疑いで手術切除を行った。切除標本は白色、辺縁やや不整で被覆を有さず、顕微鏡的には境界明瞭で著明なリンパ球、形質細胞浸潤とリンパ濾胞形成を伴い、胆管類似の腫瘍細胞が不明瞭な管状〜充実性の増殖を示した。免疫染色で腫瘍組織全体にスリット状〜不規則分枝状の血管増生を認め、EMAは癌病変の腺腔内部に陽性を示した。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J02969&link_issn=&doc_id=20111122170003&doc_link_id=%2Fab8livec%2F2011%2F001702%2F003%2F0082-0091%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8livec%2F2011%2F001702%2F003%2F0082-0091%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

State of the Art 粘液産生胆管内乳頭状腺癌の1例

松田史博, 岡部純弘, 赤穂宗一郎, 越川頼光, 竹田治彦, 犬塚義, 中島潤, 金坂卓, 恵荘裕嗣, 坂本梓, 邊見慎一郎, 金秀基, 石川哲朗, 齊藤澄夫, 波多野貴昭, 西川浩樹, 関川昭, 津村剛彦, 喜多竜一, 圓尾隆典, 木村達, 大崎往夫, 若狭朋子

肝胆膵画像 13 ( 3 ) 318 - 321 2011年5月

記述言語：日本語出版者・発行元：(株)医学書院

66歳女。検診で肝腫瘤を指摘され当科紹介となった。腹部USで肝左様に境界明瞭、辺縁に帯状の高エコー像、内部に不整形の低エコー領域を有し一部石灰化を伴う腫瘍を認め、ソナゾイド造影では辺縁高エコー部位にのみ流入を認めた。腹部CTでは肝S4に造影で濃染される乳頭状隆起を伴う嚢胞性腫瘍を認め、胆管外側枝は拡張していた。腹部MRIではT2強調像でS4に内部に不均一な低信号と高信号が混在する腫瘍を認めた。ERCPで乳頭開口部は軽度開大しており、通常の胆管造影では左肝管付近に陰影欠損を認め、末梢は描出されず、バルーン造影では拡張した内側枝を認め、IDUSでは腫瘍内に高エコーで丈の高い乳頭状隆起がみられた。S4を主体とする粘液産生胆管内乳頭状腫瘍と診断し、一部がS8まで進展していたため拡大肝左葉切除術、右後枝-小腸吻合、Roux-en Y再建術を施行した。病理学的所見で胆管内に乳頭状に発育する腫瘍を認め、腫瘍細胞の形態は膵胆管上皮型、低異型度の乳頭状腺癌であった。MUC染色ではMUC1陽性、MUC2、MUC5ACは陰性で、MIB-index 4.3%であった。

DOI： 10.11477/mf.1428100400

researchmap

胃ESD後の人工胃潰瘍治癒に対する前向き比較検討 PPI 8週vs.PPI 4週後レバミピド4週vs.PPI 1週+レバミピド8週投与の比較

今川敦, 藤木茂篤, 赤穂宗一郎, 関博之, 井口俊博, 友田健, 窪田淳一, 竹本浩二, 柘野浩史, 平良明彦, 竹中龍太

Gastroenterological Endoscopy 51 ( Suppl.2 ) 2191 - 2191 2009年9月

　前のページ - 次のページ　

<赤穂 宗一郎>

論文 - 赤穂 宗一郎

<赤穂　宗一郎>

論文 - 赤穂　宗一郎